Home>>Signaling Pathways>> Immunology/Inflammation>> Reactive Oxygen Species>>4-hydroperoxy Cyclophosphamide
4-hydroperoxy Cyclophosphamide 目录号 GC42401

An activated analog of cyclophosphamide

规格 价格 库存 购买数量
1mg
¥962.00
现货
5mg
¥1,807.00
现货
10mg
¥3,562.00
现货
25mg
¥7,540.00
现货

Customer Review

Based on customer reviews.

电话:400-920-5774 Email: sales@glpbio.cn

Sample solution is provided at 25 µL, 10mM.

质量管理

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 39800-16-3 SDF Download SDF
别名 4-OOH-CY
化学名 2-[bis(2-chloroethyl)amino]tetrahydro-2-oxido-2H-1,3,2-oxazaphosphorin-4-yl, hydroperoxide
Canonical SMILES O=P1(N(CCCl)CCCl)OCCC(OO)N1
分子式 C7H15Cl2N2O4P 分子量 293.1
溶解度 30mg/mL in DMSO,Souble in chloroform and dichloromethane. Prepare for immediate use. Do not store after dissloved 储存条件 Store at -80°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • 摩尔浓度计算器

  • 稀释计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

产品描述

4-hydroperoxy Cyclophosphamide (4-OOH-CY) is the active metabolite form of the prodrug Cyclophosphamide. 4-OOH-CY crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS).[1] Formulations containing the prodrug Cyclophosphamide are used to treat lymphomas and autoimmune disorders.[2],[3]

Reference:
[1]. Strauss, G., Westhoff, M.-A., Fischer-Posovszky, P., et al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ. 15(2), 332-343 (2008).
[2]. Ahmed, A.R., and Hombal, S.M. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J. Am. Acad. Dermatol. 11(6), 1115-1126 (1984).
[3]. Appel, G.B. New and future therapies for lupus nephritis. Cleve. Clin. J. Med. 79(2), 134-140 (2012).